Rami Manochakian: MARIPOSA Trial and Latest Developments in the Treatment of EGFR+ NSCLC
Jun 30, 2025, 14:51

Rami Manochakian: MARIPOSA Trial and Latest Developments in the Treatment of EGFR+ NSCLC

Rami Manochakian, Vice President of the North American Neuroendocrine Tumor Society, shared a post on X about a paper he co-authored with colleagues published in ASCO Daily News:

“Hot off the press.
Just published on ASCO Daily News.
Editorial Article by our team, Mayo Clinic Comprehensive Cancer Center on:
MARIPOSA trial and latest developments in the Treatment of EGFR+ non-small cell lung cancer (NSCLC).
Very proud of outstanding 1st author/mentee, chief fellow Reema Tawfiq, and excited to co-author first article with my amazing friend/colleague and new chair Vamsi Velcheti.”

Title: The Butterfly Effect: Rethinking First-Line Therapy in Advanced EGFR-Mutant NSCLC After MARIPOSA

Authors: Reema Tawfiq, Rami Manochakian, Vamsi Velcheti

You can read the Full Article in ASCO Daily News.

Rami Manochakian: MARIPOSA Trial and Latest Developments in the Treatment of EGFR+ NSCLC

More posts featuring Rami Manochakian.